The Asia Pacific transfection reagents and equipment market was valued at US$ 222.23 million in 2022 and is expected to reach US$ 414.29 million by 2030; it is estimated to register at a CAGR of 8.1% from 2022 to 2030.
Hence, people are opting for genetic profiling for the early detection and personalized treatment of hereditary cancer cases. BRCA1 and BRCA2 are sometimes referred to as tumor suppressor genes. People who inherit the harmful variants of one of these genes are at a greater risk of several cancers, most notably breast and ovarian cancer, among other types. These people also tend to develop cancer at younger ages compared to people who do not have variations in the said genes. Studies focused on nucleic acid processing by cancer cells are likely to help understand cancer metabolism. DNA is typically packaged into a viral or non-viral particle to be transferred into the cell that is to be transfected.
Gene transfer has been proposed as a new approach to enhance the effectiveness of antitumor drugs in treating intractable or metastatic cancers. The association of gene therapy and drugs (similar therapy) has been reported to strengthen the antiproliferative effects of classical treatments in lung, colorectal, pancreatic, bladder, and breast cancers, among others. Thus, the elevating economic burden of cancer bolsters the Asia Pacific transfection reagents and equipment market.
According to a study published in 2023 in the Journal of the American Medical Association, chronic kidney disease (CKD) prevalence in people aged 18 years or older in Mainland China is recorded at 8.2%. Moreover, the latest data from the International Agency for Research on Cancer (IARC) indicates that the estimated age-standardized rate (ASR) for stomach cancer in China is 21 per 100,000, and the crude rate is 33.06; for pancreatic cancer, the ASR is 5 per 100,000 with the crude rate of 8.6. As per the same source, the estimated number of new cases of stomach cancer and pancreatic cancer in people aged 0-74 in 2020 (for both sexes) was 478,508 and 124,994, respectively. Thus, the high burden of chronic diseases propels the demand for CGTs in China, in turn, fueling the transfection reagents and equipment market growth.
Growing Economic Burden of Cancer Boosts Asia Pacific Transfection Reagents and Equipment Market
According to the World Health Organization (WHO), cancer is one of the leading causes of death worldwide, and it accounted for ~10 million deaths in 2020. As per the International Agency for Research on Cancer, the global cancer burden is likely to increase with the addition of 30.2 million more cases by 2040. According to the Breast Cancer Organization, approximately 5-10% of breast cancer cases worldwide are hereditary and are caused by abnormal genes passed from generations. According to the article "Lifestyle, Genetic Risk and Incidence of Cancer," published in the International Journal of Epidemiology in 2023, nearly 33% of cancer conditions that occur are hereditary, and the risk of genetic mutations is high in the disease.Hence, people are opting for genetic profiling for the early detection and personalized treatment of hereditary cancer cases. BRCA1 and BRCA2 are sometimes referred to as tumor suppressor genes. People who inherit the harmful variants of one of these genes are at a greater risk of several cancers, most notably breast and ovarian cancer, among other types. These people also tend to develop cancer at younger ages compared to people who do not have variations in the said genes. Studies focused on nucleic acid processing by cancer cells are likely to help understand cancer metabolism. DNA is typically packaged into a viral or non-viral particle to be transferred into the cell that is to be transfected.
Gene transfer has been proposed as a new approach to enhance the effectiveness of antitumor drugs in treating intractable or metastatic cancers. The association of gene therapy and drugs (similar therapy) has been reported to strengthen the antiproliferative effects of classical treatments in lung, colorectal, pancreatic, bladder, and breast cancers, among others. Thus, the elevating economic burden of cancer bolsters the Asia Pacific transfection reagents and equipment market.
Asia Pacific Transfection Reagents and Equipment Market Overview
The Asia Pacific region is classified into China, Japan, India, South Korea, Australia and rest of Asia Pacific. China holds the largest market share in the year 2022. Asia Pacific countries such as China, India, Singapore and more with a well-established healthcare system as well as fast-growing pharmaceutical and medical industries. These countries have many healthcare facilities providing treatment and care services to cancer patients. According to an NIH study, yearly patient admissions in cancer hospitals in China climbed from 1.10 million to 3.24 million during 2010-2020.According to a study published in 2023 in the Journal of the American Medical Association, chronic kidney disease (CKD) prevalence in people aged 18 years or older in Mainland China is recorded at 8.2%. Moreover, the latest data from the International Agency for Research on Cancer (IARC) indicates that the estimated age-standardized rate (ASR) for stomach cancer in China is 21 per 100,000, and the crude rate is 33.06; for pancreatic cancer, the ASR is 5 per 100,000 with the crude rate of 8.6. As per the same source, the estimated number of new cases of stomach cancer and pancreatic cancer in people aged 0-74 in 2020 (for both sexes) was 478,508 and 124,994, respectively. Thus, the high burden of chronic diseases propels the demand for CGTs in China, in turn, fueling the transfection reagents and equipment market growth.
Asia Pacific Transfection Reagents and Equipment Market Segmentation
The Asia Pacific transfection reagents and equipment market is segmented based on product, method, application, end user, and country.- Based on product, the Asia Pacific transfection reagents and equipment market is bifurcated into reagents and instruments. The reagents segment held a larger share in 2022.
- In terms of method, the Asia Pacific transfection reagents and equipment market is segmented into viral methods, non-viral methods, and hybrid methods. The non-viral methods segment held the largest share in 2022. The viral segment is subcategorized into retrovirus, adenovirus, adeno associated virus, and herpes virus. The non-viral segment is bifurcated into physical/mechanical method and chemical method. Further, the physical/mechanical method segment is subcategorized into electroporation, microinjection, biolistic method, laser method, magnetofection, and sonoporation. Also, the chemical method segment is subcategorized into liposomal based/high lipid and non-liposomal/high lipid based.
- By application, the Asia Pacific transfection reagents and equipment market is segmented into biomedical research, protein production, and therapeutic delivery. The biomedical research segment held the largest share in 2022.
- Based on end user, the Asia Pacific transfection reagents and equipment market is bifurcated into academics & research institutes and pharmaceutical & biotechnology companies. The academics & research institutes segment held a larger share in 2022.
- Based on country, the Asia Pacific transfection reagents and equipment market is categorized into Australia, China, India, Japan, South Korea, and the Rest of Asia Pacific. China dominated the Asia Pacific transfection reagents and equipment market in 2022.
Table of Contents
1. Introduction
2. Executive Summary
3. Research Methodology
4. Asia Pacific Transfection Reagents and Equipment Market - Key Market Dynamics
5. Transfection Reagents and Equipment Market - Asia Pacific Market Analysis
6. Asia Pacific Transfection Reagents and Equipment Market Analysis - by Product
7. Asia Pacific Transfection Reagents and Equipment Market Analysis - by Modality
8. Asia Pacific Transfection Reagents and Equipment Market Analysis - by Application
9. Asia Pacific Transfection Reagents and Equipment Market Analysis - by End Users
10. Asia Pacific Transfection Reagents and Equipment Market -Country Analysis
11. Transfection Reagents and Equipment Market -Industry Landscape
12. Company Profiles
13. Appendix
Companies Mentioned
- Thermo Fisher Scientific Inc
- Promega Corp
- F. Hoffmann-La Roche Ltd
- Bio-Rad Laboratories Inc
- Mirus Bio LLC
- QIAGEN NV
- Merck KGaA
- Lonza Group AG
- MaxCyte Inc
